Ophthalmology, Massachusetts Eye and Ear, Howe Laboratory, Harvard Medical School, Boston, Massachusetts, USA.
Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Br J Ophthalmol. 2019 Sep;103(9):1204-1208. doi: 10.1136/bjophthalmol-2019-313835. Epub 2019 Feb 13.
Recurrent corneal erosion syndrome (RCES) is a disorder characterised by a dysfunctional epithelial ecosystem. It often begins after trauma, or in the setting of epithelial basement membrane degeneration or dystrophy. Historically, RCES has been understood as a structural derangement of the anterior corneal architecture. More recently, studies have demonstrated the important role of neuropeptides in corneal homoeostasis. Thus, RCES may also be understood as a disorder of corneal epithelial cell biology. Management of RCES can be challenging, but newer therapies have demonstrated improved efficacy for this condition. This review examines the aetiology and pathogenesis of RCES, and provides an update on current and emerging treatment modalities for the management of this disorder.
复发性角膜糜烂综合征(RCES)是一种以功能失调的上皮生态系统为特征的疾病。它通常在创伤后或上皮基底膜变性或营养不良的情况下开始。历史上,RCES 被认为是前角膜结构的一种结构紊乱。最近的研究表明神经肽在角膜稳态中起着重要作用。因此,RCES 也可以被理解为一种角膜上皮细胞生物学的紊乱。RCES 的治疗可能具有挑战性,但较新的治疗方法已证明对这种疾病的疗效有所提高。本综述探讨了 RCES 的病因和发病机制,并提供了关于这种疾病管理的当前和新兴治疗方法的最新信息。